医学临床研究
  2025年5月9日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (12): 1892-1894    DOI: 10.3969/j.issn.1671-7171.2023.12.020
  论著 本期目录 | 过刊浏览 | 高级检索 |
新辅助放化疗对食管癌术后ki-67、CD44v6及PD-1/PD-L1表达的影响
巩想平1, 史永铁2*
1.宝鸡高新医院消化内科,陕西 宝鸡 721000;
2.陕西省扶风县人民医院肿瘤放疗科,陕西 宝鸡 722299
The Effect of Neoadjuvant Radiotherapy and Chemotherapy on the Expression of ki-67, CD44v6, and PD-1/PD-L1 after Esophageal Cancer Surgery
GONG Xiangping, SHI Yongtie
Department of Gastroenterology,Baoji High-tech Hospital,Baoji Shaanxi 721000
全文: PDF (1280 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨新辅助放化疗对食管癌患者术后细胞核蛋白(ki-67)、整合膜糖蛋白(CD44v6)及程序性细胞死亡蛋白-1(PD-1)/程序性细胞死亡蛋白配体1(PD-L1)表达的影响。【方法】76例食管癌患者随机分为观察组和对照组,每组38例。两组患者均行常规食管癌根治术,观察组患者在术前行新辅助放化疗治疗。比较两组患者围术期指标、临床疗效、术后ki-67、CD44v6、PD-1/PD-L1表达水平及并发症发生率。【结果】两组患者术中出血量、手术时间、胸液量比较,差异均无统计学意义(P>0.05);观察组住院天数少于对照组(P<0.05)。观察组患者客观有效率为76.32%(29/38),显著高于对照组的52.63%(20/38)(P<0.05)。观察组患者术后ki-67蛋白阳性表达率和CD44v6、PD-1/PD-L1水平均低于对照组(P<0.05)。两组患者并发症总发生率比较,差异无统计学意义(P>0.05)。【结论】术前新辅助放化疗能够有效提高食管癌患者的临床疗效和免疫功能,且安全性较高。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
巩想平
史永铁
关键词 食管肿瘤/外科学食管肿瘤/放射疗法食管肿瘤/药物疗法Ki-67抗原透明质酸受体    
Abstract:【Objective】 To explore the effects of neoadjuvant radiotherapy and chemotherapy on the expression of nuclear protein (ki-67), integrated membrane glycoprotein (CD44v6), and programmed cell death protein-1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) in postoperative esophageal cancer patients. 【Method】A total of 76 patients with esophageal cancer were randomly divided into an observation group and a control group, with 38 cases in each group. Both groups of patients underwent routine esophageal cancer radical surgery, while the observation group received neoadjuvant chemotherapy before surgery. We compared perioperative indicators, clinical efficacy, postoperative ki-67, CD44v6, PD-1/PD-L1 expression levels, and incidence of complications between two groups of patients. 【Results】There was no statistically significant difference in intraoperative bleeding, surgical time, and pleural fluid volume between the two groups of patients (P>0.05); The length of hospital stay in the observation group was less than that in the control group (P<0.05). The objective effective rate of the observation group patients was 76.32% (29/38), significantly higher than the control group's 52.63% (20/38) (P<0.05). The positive expression rate of ki-67 protein and the levels of CD44v6 and PD-1/PD-L1 in the observation group were lower than those in the control group after surgery (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups of patients (P>0.05). 【Conclusion】Preoperative neoadjuvant radiotherapy and chemotherapy can effectively improve the clinical efficacy and immune function of esophageal cancer patients, with high safety.
Key wordsEsophageal Neoplasms/SU    Esophageal Neoplasms/RT    Esophageal Neoplasms/DT    Ki-67 Antigen    Hyaluronan Receptors
收稿日期: 2022-07-26     
中图分类号:  R735.1  
通讯作者: *E-mail:474043293@qq.com   
引用本文:   
巩想平, 史永铁. 新辅助放化疗对食管癌术后ki-67、CD44v6及PD-1/PD-L1表达的影响[J]. 医学临床研究, 2023, 40(12): 1892-1894.
GONG Xiangping,SHI Yongtie. The Effect of Neoadjuvant Radiotherapy and Chemotherapy on the Expression of ki-67, CD44v6, and PD-1/PD-L1 after Esophageal Cancer Surgery. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1892-1894.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.12.020     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I12/1892
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn